Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Cardiology Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Photodynamic Therapy: A Look at How This Treatment Fits Into Today’s Retina Practice

By: Jordana G. Fein, MD, MS; Rishi P. Singh, MD

Webinar Credits: 1

Eye care professionals may not know how to effectively identify patients in clinic who will benefit from Photodynamic Therapy (PDT), including those with persistent disease activity. This webinar includes discussions on real-world clinical scenarios in which the use of photodynamic therapy alone or in combination with anti-VEGFs can be a more efficacious treatment option than using anti-VEGFs alone, particularly in the setting of persistent disease activity.

TARGET AUDIENCE
This certified CME activity is designed for retina specialists and ophthalmologists involved in the management of retinal diseases.

Expiration Date: Wednesday, June 30, 2021
Release Date: July 7, 2020

Learning Objectives

Upon completion of this activity, participants will be better able to:

  • Summarize the clinical benefits of PDT in patients with retinal disorders and in those with persistent disease activity.
  • Design a treatment regimen based on a personalized medicine approach for patients who do not respond adequately to anti-VEGF injections.
  • Identify methods for effective PDT delivery in clinic settings, including dosing, infusion periods, and determination of treatment size.
  • Differentiate the benefits of half-fluence PDT and full-fluence PDT on a real-world population.

Accreditation and Designation Statement

Provided by Evolve Medical Education

Accreditation Statement

Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Participation Method

In order to obtain credit, complete the pretest, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:

Internet Explorer 11 for Windows

Edge (recent versions; Chromium-based) for Windows

Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux

Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux

Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:

4GB+ RAM

Recommended internet speed 5Mbps+

 

Faculty and Disclosures

 

 

Jordana G. Fein, MD, MS

Staff Physician, The Retina Group of Washington
Fairfax, Virginia

 

 

Rishi P. Singh, MD

Staff Physician, Cole Eye Institute
Medical Director, Clinical Systems Office Cleveland Clinic
Associate Professor of Ophthalmology, Case Western Reserve University
Cleveland, Ohio

 

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Jordana G. Fein, MD, MS, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support: Apellis, Lexitas, Opthea, and Regeneron Pharmaceuticals. Speaker’s Bureau: Regeneron Pharmaceuticals.

Rishi P. Singh, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Bausch + Lomb, Genentech, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Apellis and Graybug.

 

The Evolve staff and planners have no financial relationships with commercial interests.

Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.

 

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, or Bausch + Lomb.

Video Resources

BackNext

Test

Instructions

In order to obtain credit, complete the pretest, proceed through the program, complete the post-test, evaluation and submit for credit.

 

Step 1 of 2

  • a. 1b. 2c. 3d. 4e. 5
  • a. 1b. 2c. 3d. 4e. 5
  • AgreeNeutralDisagree
    Summarize the clinical benefits of PDT in patients with retinal disorders and in those with persistent disease activity
    Design a treatment regimen based on a personalized medicine approach for patients who do not respond adequately to anti-VEGF injections
    Identify methods for effective PDT delivery in clinic settings, including dosing, infusion periods, and determination of treatment size
    Differentiate the benefits of half-fluence PDT and full-fluence PDT on a real-world population
Back